{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:49:03Z","timestamp":1762148943700,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.expneurol.2009.10.004","type":"journal-article","created":{"date-parts":[[2009,10,14]],"date-time":"2009-10-14T14:15:32Z","timestamp":1255529732000},"page":"79-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or l-DOPA in MPTP-treated common marmosets"],"prefix":"10.1016","volume":"221","author":[{"given":"K.A.","family":"Stockwell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.K.A.","family":"Scheller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.M.","family":"Iravani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2009.10.004_bib1","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/mds.21500","article-title":"Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome","volume":"22","author":"Antonini","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.10.004_bib2","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2165\/00023210-200721120-00007","article-title":"Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease","volume":"21","author":"Baldwin","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.expneurol.2009.10.004_bib3","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1212\/WNL.61.6_suppl_3.S12","article-title":"Clinical strategies to prevent and delay motor complications","volume":"61","author":"Barone","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2009.10.004_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.expneurol.2004.11.013","article-title":"Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates","volume":"192","author":"Bibbiani","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2009.10.004_bib5","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0022-3565(25)24503-7","article-title":"Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys","volume":"272","author":"Blanchet","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2009.10.004_bib6","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1586\/14737175.7.10.1391","article-title":"Role of dopamine agonists in Parkinson's disease: an update","volume":"7","author":"Bonuccelli","year":"2007","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.expneurol.2009.10.004_bib7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1353-8020(02)00029-9","article-title":"Levodopa response motor complications GABA receptors and preproenkephalin expression in human brain","volume":"8","author":"Calon","year":"2002","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2009.10.004_bib8","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/S1471-1931(00)00026-4","article-title":"Dopamine\u2013receptor stimulation: biobehavioral and biochemical consequences","volume":"23","author":"Calon","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.expneurol.2009.10.004_bib9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ana.410240303","article-title":"Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms: Part I","volume":"24","author":"Fabbrini","year":"1988","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2009.10.004_bib10","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/mds.22063","article-title":"Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study","volume":"23","author":"Garcia Ruiz","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.10.004_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-3-7091-0643-3_10","article-title":"Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease","author":"Gerlach","year":"2003","journal-title":"J. Neural. Transm. Suppl."},{"key":"10.1016\/j.expneurol.2009.10.004_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00002826-200007000-00005","article-title":"Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys","volume":"23","author":"Hadj","year":"2000","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2009.10.004_bib13","first-page":"1044","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial","volume":"61","author":"Holloway","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.expneurol.2009.10.004_bib14","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1212\/WNL.58.suppl_1.S42","article-title":"Long-term studies of dopamine agonists","volume":"58","author":"Hubble","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2009.10.004_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.expneurol.2006.10.005","article-title":"Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets","volume":"204","author":"Jackson","year":"2007","journal-title":"Exp. Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.expneurol.2009.10.004_bib16","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00019052-200312001-00002","article-title":"Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease","volume":"16","author":"Jenner","year":"2003","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.expneurol.2009.10.004_bib17","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1212\/WNL.62.1_suppl_1.S47","article-title":"Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation","volume":"62","author":"Jenner","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2009.10.004_bib18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of l-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.expneurol.2009.10.004_bib19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/mds.20276","article-title":"Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges","volume":"20","author":"Katzenschlager","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.10.004_bib20","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s00702-007-0719-3","article-title":"Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation","volume":"114","author":"Kehr","year":"2007","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.expneurol.2009.10.004_bib21","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.clinthera.2006.08.004","article-title":"A review of the receptor-binding and pharmacokinetic properties of dopamine agonists","volume":"28","author":"Kvernmo","year":"2006","journal-title":"Clin. Ther."},{"key":"10.1016\/j.expneurol.2009.10.004_bib22","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/mds.10281","article-title":"Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients","volume":"17","author":"Manson","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.10.004_bib23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1006\/exnr.2002.8055","article-title":"Both short- and long-acting D-1\/D-2 dopamine agonists induce less dyskinesia than l-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus)","volume":"179","author":"Maratos","year":"2003","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2009.10.004_bib24","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/mds.1149","article-title":"Antiparkinsonian activity and dyskinesia risk of ropinirole and l-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus)","volume":"16","author":"Maratos","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.10.004_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1600-0404.1998.tb00633.x","article-title":"Long-term intraduodenal infusion of a water based levodopa\u2013carbidopa dispersion in very advanced Parkinson's disease","volume":"97","author":"Nilsson","year":"1998","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.expneurol.2009.10.004_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mds.21060","article-title":"Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa?","volume":"22","author":"Nutt","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.10.004_bib27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","article-title":"Continuous dopamine\u2013receptor treatment of Parkinson's disease: scientific rationale and clinical implications","volume":"5","author":"Olanow","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.expneurol.2009.10.004_bib28","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group","volume":"284","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.expneurol.2009.10.004_bib29","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/mds.870130207","article-title":"De novo administration of ropinirole and bromocriptine induces less dyskinesia than l-dopa in the MPTP-treated marmoset","volume":"13","author":"Pearce","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.10.004_bib30","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic l-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus)","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.10.004_bib31","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/mds.20988","article-title":"Development of dyskinesias in a 5-year trial of ropinirole and l-dopa","volume":"21","author":"Rascol","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.10.004_bib32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ana.410240116","article-title":"Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism","volume":"24","author":"Sage","year":"1988","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2009.10.004_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/mds.870110203","article-title":"An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets","volume":"11","author":"Smith","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.10.004_bib34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/01.WNF.0000220818.71231.DF","article-title":"Switching from levodopa to the long-acting dopamine D2\/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates","volume":"29","author":"Smith","year":"2006","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2009.10.004_bib35","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/mds.10200","article-title":"Repeated administration of piribedil induces less dyskinesia than l-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation","volume":"17","author":"Smith","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.10.004_bib36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/WNF.0b013e318065b088","article-title":"Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia","volume":"31","author":"Stacy","year":"2008","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2009.10.004_bib37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1468-1331.2007.01674.x","article-title":"Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease","volume":"15","author":"Steiger","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.expneurol.2009.10.004_bib38","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/brain\/awf214","article-title":"Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease","volume":"125","author":"Stocchi","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2009.10.004_bib39","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archneur.62.6.905","article-title":"Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study","volume":"62","author":"Stocchi","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.expneurol.2009.10.004_bib40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.expneurol.2009.07.011","article-title":"Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction","volume":"219","author":"Stockwell","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2009.10.004_bib41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.expneurol.2008.01.019","article-title":"Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets","volume":"211","author":"Stockwell","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2009.10.004_bib42","first-page":"CD006564","article-title":"Dopamine agonist therapy in early Parkinson's disease.","author":"Stowe","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.expneurol.2009.10.004_bib43","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1517\/13543784.12.11.1803","article-title":"Dopamine agonists in Parkinson's disease","volume":"12","author":"Tintner","year":"2003","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"10.1016\/j.expneurol.2009.10.004_bib44","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/mds.21630","article-title":"The course of dyskinesia induction by different treatment schedules of levodopa in Parkinsonian rats: is continuous dopaminergic stimulation necessary?","volume":"23","author":"Tsironis","year":"2008","journal-title":"Mov. Disord."},{"issue":"Suppl. 11","key":"10.1016\/j.expneurol.2009.10.004_bib45","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1002\/mds.20459","article-title":"Pathophysiology of motor fluctuations in Parkinson's disease","volume":"20","author":"Widnell","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.10.004_bib46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1358\/dot.2006.42.1.932510","article-title":"Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease","volume":"42","author":"Zareba","year":"2006","journal-title":"Drugs Today (Barc.)"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448860900421X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448860900421X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:45:11Z","timestamp":1762148711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448860900421X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S001448860900421X"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2009.10.004","relation":{},"ISSN":["0014-4886"],"issn-type":[{"type":"print","value":"0014-4886"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or l-DOPA in MPTP-treated common marmosets","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2009.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}